| Literature DB >> 31101967 |
Lisa Lavan1, Thomas Herrmann2, Christopher Netsch3, Benedikt Becker3, Bhaskar K Somani4,5.
Abstract
INTRODUCTION: Treatment of stone disease in anomalous kidneys can be challenging. As ureteroscopy (URS) has advanced, the number of studies reporting on outcomes of URS for stone disease in anomalous kidneys has increased. Our objective was to perform a systematic review of the literature to evaluate the outcomes of URS for stone disease in this group of patients.Entities:
Keywords: Ectopic kidney; Horseshoe kidney; Malrotation; Pelvic; RIRS; Renal anomaly; Ureteroscopy; Urolithiasis
Year: 2019 PMID: 31101967 PMCID: PMC7190593 DOI: 10.1007/s00345-019-02810-x
Source DB: PubMed Journal: World J Urol ISSN: 0724-4983 Impact factor: 4.226
Fig. 1PRISMA flowchart of the included studies
Patient demographics and case mix of the included studies
| References | Study design | Total patients | HSK | EK | MR | Other | Mean age, years (range) | Male | Female |
|---|---|---|---|---|---|---|---|---|---|
| Weizer et al. [ | Retrospective | 8 | 4 | 4 | 0 | 0 | 50.6 (35–69) | 6 | 2 |
| Molimard et al. [ | Retrospective | 17 | 17 | 0 | 0 | 0 | 34.7 (16–52) | 14 | 3 |
| Atis et al. [ | Retrospective | 20 | 20 | 0 | 0 | 0 | 40.9 (NR) | 12 | 8 |
| Bozkurt et al. [ | Retrospective | 26 | 0 | 26 | 0 | 0 | 41.1 (7–72) | 19 | 7 |
| Oḡuz et al. [ | Retrospective | 24 | 0 | 0 | 24 | 0 | 39.8 (1–71) | 18 | 6 |
| Urgulu et al. [ | Retrospective | 25 | 3 | 11 | 4 | 5 | 39.4 (NR) | 17 | 8 |
| Ding et al. [ | Retrospective | 16 | 16 | 0 | 0 | 0 | 42.9 (22–66) | 13 | 3 |
| Blackburn et al. [ | Retrospective | 20 | 20 | 0 | 0 | 0 | 48.1 (29–78) | 13 | 7 |
| Gokce et al. [ | Retrospective | 23 | 23 | 0 | 00 | 0 | 42.5 (16–78) | 18 | 5 |
| Bansal et al. [ | Retrospective | 9 | 9 | 0 | 0 | 0 | NR | 7 | 2 |
| Ergin et al. [ | Retrospective | 101 | 36 | 33 | 32 | 0 | 39.0 (1–72) | 68 | 33 |
| Singh et al. [ | Retrospective | 25 | 5 | 14 | 5 | 1 | 38.28 (NR) | 17 | 8 |
| Legemate et al. [ | Retrospective | 86 | 43 | 27 | 16 | 0 | 49.2 (NR) | 57 | 29 |
| Astolfi et al. [ | Prospective | 13 | 8 | 0 | 5 | 0 | 46.1 (NR) | 6 | 7 |
| Total | 413 | 204 | 117 | 86 | 6 | 43.4 | 285 | 128 |
HSK horseshoe kidney, EK ectopic kidney, MR malrotation
Stone size and location in the included studies
| References | Stone size mean (mm)/[mm2] | Stone size range (mm)/[mm2] | Single stone | Multiple stones | Stone position, lower pole | Stone position, midpole | Stone position, upper pole | Stone position, renal pelvis | Stone position, mixed | Stone position, upper ureter |
|---|---|---|---|---|---|---|---|---|---|---|
| Weizer et al. [ | 14 | 3–20 | 5 | 3 | 4 | 0 | 2 | 5 | (3) | 0 |
| Molimard et al. [ | 16 | 7–35 | 7 | 10 | – | – | – | 7 | 10 | 0 |
| Atis et al. [ | 17.8 | ± 4.5 | 5 | 15 | 9 | 7 | 4 | 5 | (5) | 0 |
| Bozkurt et al. [ | 17 | 10–28 | 21 | 5 | 7 | 0 | 0 | 14 | 5 | 0 |
| Oḡuz et al. [ | 13.5 | 5–30 | 24 | 0 | 9 | 3 | 2 | 10 | 0 | 0 |
| Urgulu et al. [ | [194.7] | [85–393] | 19 | 6 | 14 | 4 | 7 | 7 | (6) | 0 |
| Ding et al. [ | 29.8 | 17–42 | 4 | 12 | 1 | 1 | 0 | 2 | 12 | 0 |
| Blackburn et al. [ | 8.4 | 2–25 | 17 | 3 | 10 | NR | NR | NR | NR | 0 |
| Gokce et al. [ | 17.1 | 6–25 | 14 | 9 | 6 | 0 | 0 | 17 | 0 | 0 |
| Bansal et al. [ | 15.4 | NR | 6 | 3 | 12 | 0 | 0 | 0 | 0 | 0 |
| Ergin et al. [ | 16.1 | NR | NR | NR | 35 | 16 | 14 | 45 | (9) | 0 |
| Singh et al. [ | 14.7 | ± 4.1 mm | 15 | 10 | 11 | 8 | 5 | 11 | (12) | 2 |
| Legemate et al. [ | [84] | [4–117] | 70 | 16 | 18 | 3 | 2 | 3 | 15 | 13 |
| Astolfi et al. [ | 12.2 | 6–22 | 12 | 1 | 7 | 2 | 0 | 2 | 1 | 0 |
| Total [mean] | [16.0] | 219 | 93 | 143 | 44 | 36 | 128 | 78 | 15 |
Data on pre-operative variables
| References | Pre-operative imaging | Pre-operative urine MC and S | Peri-operative antibiotics | Pre-operative stent | Previous SWL | Previous PCNL | Previous open procedure | Previous URS | > 1 previous procedure |
|---|---|---|---|---|---|---|---|---|---|
| Weizer et al. [ | IVU or NCCT | NR | NR | 1 12.5%) | 6 | 0 | 1 | 0 | 1 |
| Molimard et al. [ | NCCT | Yes | NR | 4 (23.5%) | 8 | 4 | 2 | 3 | NR |
| Atis et al. [ | AXR and IVU or US | Yes | Yes | 0 | 4 | 4 | 4 | 0 | 4 |
| Bozkurt et al. [ | NCCT or IVU | Yes | NR | NR | 9 | 0 | 1 | 0 | 0 |
| Oḡuz et al. [ | AXR, IVU, US or NCCT | Yes | Yes | NR | 12 | 0 | 0 | 4 | 0 |
| Urgulu et al. [ | IVU and CT | Yes | NR | NR | 7 | 2 | 2 | 1 | NR |
| Ding et al. [ | AXR and IVU or NCCT | NR | Yes | NR | 7 | 1 | 0 | 0 | 1 |
| Blackburn et al. [ | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Gokce et al. [ | AXR and USS or NNCT | Yes | Yes | NR | NR | NR | NR | NR | NR |
| Bansal et al. [ | AXR, IVU, USS or NCCT | NR | Yes | NR | 2 | 5 | 0 | 0 | 0 |
| Ergin et al. [ | IVU, USS or NCCT | Yes | NR | NR | NR | NR | NR | NR | NR |
| Singh et al. [ | CTU | Yes | NR | 5 (20%) | NR | NR | NR | NR | NR |
| Legemate et al. [ | AXR, IVU or NCCT | Yes | Yes | 18 (24.7%) | 20 | 12 | 0 | 15 | NR |
| Astolfi et al. [ | AXR or NCCT | NR | NR | 11 (84.6%) | NR | NR | NR | NR | NR |
| Total | 40 (29.4%) | 75 (59.2%) | 28 (22.2%) | 10 (7.9%) | 23 (18.3%) |
AXR plain abdominal X-ray, IVU intravenous urogram, USS ultrasound scan, NCCT non-contrast computerised tomography, CTU computerised tomography urogram, NR not reported, SWL shockwave lithotripsy, PCNL percutaneous nephrolithotomy, URS ureteroscopy
Intraoperative and post-operative data from included studies
| References | Anaesthesia | Procedure | Holmium laser | Fibre size (μm) | Energy setting (J) | Energy setting (Hz) | Access sheath used | Post-operative stent | Mean operative time, min (range) | Length of stay, days (range) |
|---|---|---|---|---|---|---|---|---|---|---|
| Weizer et al. [ | NR | FURS | Yes | 200 | 0.6–1.0 | 6–10 | 4 (50%) | 8 (100%) | 126 (90–185) | NR |
| Molimard et al. [ | GA | FURS | Yes | 150 or 365 | 0.8–1.2 | 8–12 | 17 (100%) | 17 (100%) | 92 (45–140) | 1.7 (1–3) |
| Atis et al. [ | GA | SRU and FURS | Yes | 273 | 0.6–1.0 | 5–10 | 20 (100%) | 15 (75%) | 40.5 | 1.4 |
| Bozkurt et al. [ | GA | FURS | Yes | 200 | 0.8 | 10 | 0 | 12 (46%. | 52.1 (30–120) | 2.7 (1–9) |
| Oḡuz et al. [ | GA | SRU and FURS | Yes | 273 | NR | NR | 20 (83%) | 17 (71%) | 48.7 (18–135) | 1.5 (1–5) |
| Urgulu et al. [ | GA | FURS | Yes | 200 or 273 | NR | NR | 18 (72%) | NR | 48 (14–115) | NR |
| Ding et al. [ | Spinal | SRU and FURS | Yes | 200 | 0.8–1.2 | 10–15 | 16 (100%) | 16 (100%) | 92 (14–127) | 0.8 (0–3) |
| Blackburn et al. [ | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Gokce et al. [ | GA | FURS | Yes | NR | 0.8–1.2 | 8–12 | 23 (100%) | 23 (100%) | NR | 1.8 (1–3) |
| Bansal et al. [ | GA | FURS | Yes | 200 | 0.6–0.8 | 10–15 | 9 (100%) | 9 (100%) | 84.2 | NR |
| Ergin et al. [ | GA | SRU and FURS | Yes | 170 or 200 | NR | NR | NR | 50 (50%) | 47.1 | 1.9 |
| Singh et al. [ | GA | FURS | Yes | 200 or 365 | 0.5–1.0 | 10–15 | 25 (100%) | 21 (84%) | 74 | 2.48 |
| Legemate et al. [ | NR | SRU alone 47.7% FURS 32.6% Combination 17.4% | 57% | NR | NR | NR | 29 (71%) | 71 (84%) | 58 (30–120) | 1 (0.5–5) |
| Astolfi et al. [ | GA | SRU and FURS | Yes | 200 or 273 | NR | NR | NR | 13 (100%) | NR | NR |
GA general anaesthetic, SRU semirigid ureteroscopy, FURS flexible ureterorenoscopy, NR not reported
Post-operative outcomes from included studies
| References | Definition of success | Post-op imaging modality | Imaging time interval (weeks) | Overall success rate (%) | Success after single procedure | Auxiliary procedures required | Readmission | Complications Clavien I–II | Complications Clavien ≥ III |
|---|---|---|---|---|---|---|---|---|---|
| Weizer et al. [ | Stone free | AXR and IVU or NCCT | 4–12 | 75.0 | 75.0 | 0 | NR | 0 | 0 |
| Molimard et al. [ | RF ≤ 3 mm | AXR and USS or NCCT | 4 - 6 | 88.2 | 53.0 | 7 URS | 1 | 8 | 0 |
| Atis et al. [ | RF < 4 mm | IVU and USS (NCCT if RF) | 4 | 80.0 | 70.0 | 6 SWL | 0 | 5 | 0 |
| Bozkurt et al. [ | RF ≤ 2 mm | NCCT | 4 | 84.7 | NR | NR | NR | 3 | 2 |
| Oḡuz et al. [ | RF ≤ 3 mm | IVU and USS (NCCT if RF) | 4 | 83.3 | 75.0 | 1 SWL 1 URS | 1 | 11 | 2 |
| Urgulu et al. [ | Complete clearance | NCCT | 4 | 88.0 | 64.0 | 6 URS 3 SWL | NR | 3 | 0 |
| Ding et al. [ | Not defined | AXR and USS | 4 | 87.5 | 62.5 | 6 URS | NR | 3 | 0 |
| Blackburn et al. [ | RF < 4 mm | AXR or CT | NR | 84.0 | NR | NR | NR | NR | NR |
| Gokce et al. [ | RF < 3 mm | AXR and/or USS/NCCT | 2 - 6 | 73.9 | NR | NR | 0 | 4 | 0 |
| Bansal et al. [ | RF ≤ 4 mm | AXR and USS or NCCT | 4 | 88.9 | 67.7 | 3 URS | 1 | 4 | 0 |
| Ergin et al. [ | RF < 3 mm | NR | NR | 76.9 | NR | 8 URS | NR | 12 | 2 |
| Singh et al. [ | RF < 2 mm | AXR and USS | 4 | 88.0 | 72.0 | 3 PCNL | NR | 5 | 1 |
| Legemate et al. [ | RF ≤ 1 mm | AXR and USS or NCCT | NR | 58.3 | NR | 15 | 12 | 2 | 3 |
| Astolfi et al. [ | RF < 2 mm | AXR or NCCT | 12 | 75.0 | NR | NR | 0 | 1 | 0 |
| Overall | 82.3% ( | 76.6% ( | 18 | 15 | 61 (14.8%) | 10 (2.4%) |
RF residual fragments, AXR plain abdominal X-ray, IVU intravenous urogram, USS ultrasound scan, NCCT non-contrast computed tomogram, URS ureteroscopy, SWL shockwave lithotripsy, PCNL percutaneous nephrolithotomy
Studies reporting on outcomes for individual data for HSK, EK and MR
| Mean stone burden [range] | Percentage of lower pole stones (%) | Success after single procedure | Overall success (%) | ||
|---|---|---|---|---|---|
| Urgulu et al. [ | HSK ( | 253 mm2 ± 103.7 | 50.0 | 66.7% | 66.7 |
| EK ( | 237.7 mm2 ± 94.4 (lumbar) 168.8 mm2 ± 101.7 (pelvic) | 57.1 33.3 | 61.5% | 100 | |
| MR ( | 201.3 mm2 ± 109.5 | 75.0 | 100% | 100 | |
| Ergin et al. [ | HSK ( | 17.8 mm ± 4.5 | 30.6 | NR | 72.2 |
| EK ( | 17.0 mm ± 5.1 | 36.4 | NR | 83.6 | |
| MR ( | 13.4 mm ± 3.7 | 37.5 | NR | 75.0 | |
| Legemate et al. [ | HSK ( | 70 mm2 [46–134] | 52.1 | NR | 77.3 |
| EK ( | 120 mm2 [79–263] | 30.0 | NR | 20.0 | |
| MR ( | 62 mm2 [0–148] | 37.5 | NR | 71.4 |
HSK horseshoe kidney, EK ectopic kidney, MR malrotation
Complications graded as per Clavien–Dindo classification
| References | Clavien I–II | Clavien ≥ III |
|---|---|---|
| Weizer et al. [ | None | None |
| Molimard et al. [ | Stent symptoms Haematuria Pyelonephritis | None |
| Atis et al. [ | Post-operative pyrexia Haematuria | None |
| Bozkurt et al. [ | Post-operative pyrexia Haematuria Urinary tract infection | Ureteric colic requiring JJ stent |
| Oḡuz et al. [ | Post-operative pyrexia Ureteric colic (conservative management) | Ureteric colic requiring surgical intervention |
| Urgulu et al. [ | Urosepsis Pyelonephritis Ureteric colic (conservative management) | None |
| Ding et al. [ | Post-operative pyrexia | None |
| Blackburn et al. [ | Complications not reported | Complications not reported |
| Gokce et al. [ | Haematuria Post-operative pyrexia | None |
| Bansal et al. [ | Post-operative pyrexia Stent symptoms Pyelonephritis | None |
| Ergin et al. [ | Haematuria Post-operative pyrexia | Ureteric colic requiring JJ stent |
| Singh et al. [ | Post-operative pyrexia Urinary tract infection | Ureteric colic requiring JJ stent |
| Legemate et al. [ | Post-operative pyrexia Urosepsis | IIIa not defined IIIb not defined IVa Urosepsis requiring nephrostomy and ITU support |
| Astolfi et al. [ | Haematuria | None |
Fig. 2Risk of bias analysis
Fig. 3Tips and practical guidance for management